Journals / Medicine Science / 2021 / Cilt: 10 - Sayı: 3

Serum ischemia modified albumin level in acute migraine attacks

Pages
794–797
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We found that serum IMA levels in acute migraine attacks were significantly higher than in the control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the pathogenesis of migraines is not yet fully known, oxidative stress is thought to play an important role in the pathogenesis of this disease.
📊
Key Findings & Data:The study included a control group consisting of 40 healthy individuals and a group of 40 patients admitted to the emergency department with migraine attacks.
💡
Conclusion & Impact:We found that serum IMA levels in acute migraine attacks were significantly higher than in the control group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the pathogenesis of migraines is not yet fully known, oxidative stress is thought to play an important role in the pathogenesis of this disease. In our study, we aimed to evaluate the serum level of ischemia-modified albumin (IMA), one of the systemic markers of oxidative stress, in acute migraine attacks admitted to the emergency department. The study included a control group consisting of 40 healthy individuals and a group of 40 patients admitted to the emergency department with migraine attacks. Serum IMA levels were studied using the ELISA kit. The average age of the migraine group was 39.9±8.2 and 31 were female. The average age of the control group was 42.5±9.2 and 29 were women. There was no difference between groups in terms of age and gender (p=0.18, p=0.79, respectively). Mean serum IMA levels were significantly higher in the migraine group than in the control group (p=0.001). On receiver operating characteristic curve (ROC) analysis, use of optimal IMA cutoff level of 92.6 ng/ml was associated with 70% sensitivity and 55% specificity (AUC= 0.713, 95% CI: 0.600-0.826, p= 0.001). In the migraine group the mean attack frequency was 2.55±1.3 within three months, with an average duration of migraine 8.87±4.76 years. The mean Visual Analogue Scale (VAS) was 8±1.2. A positive correlation was found between IMA levels and duration of migraine (r= 0.621, p= 0.001), attack frequency (r= 0.568, p = 0.001) and VAS (r= 0.352, p= 0.026). We found that serum IMA levels in acute migraine attacks were significantly higher than in the control group.

🔖

Cite This Article

Gul, E., Gurger, M. (2022). Serum ischemia modified albumin level in acute migraine attacks. Medicine Science, Cilt: 10 - Sayı: 3, 794–797. https://ajindex.com/articles/579636

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dodick DW. Migraine. Lancet 2018;391:1315-30.
  2. Say B, Badem ND, Ergun U. Serum levels of ischemia-modified albumin and prolidase in migraine subjects. J Health Sci Med. 2020;3:31-5.
  3. Ersoy A, Yasar H, Mertoglu C, et al. Is ischemia associated with the formation of White matter lesions in migraine? Clin Neurol Neurosurg. 2020;193:105770. Cakina S, Yücel S, Polat CC, et al. Oxidatıve stress parameters in patients with migraine without aura. Namık Kemal Tıp Dergisi. 2020;8:31-5.
  4. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia a preliminary report. Emerg Med J. 2000;19:311-5.
  5. Askin L, Sercelik A, Tanriverdi O, et al. A novel systemic indicator of cardiovasculer ischemic events: Ischemia modified albumin levels. MN Kardiyoloji. 2019;26:198-202.
  6. Menon B, Ramalingam K, Krishna V. Study of ischemia modified albumin as a biomarker in acute ischaemic stroke. Ann Neurosci. 2018;25:187-90.
  7. Aydin O, Ellidag HY, Eren E, et al. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochemia Medica. 2014;24:383-9.
  8. Tunc S, Atagun MI, Neselioglu S et al. Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology. 2019;29:123-9.
  9. Gunduz A, Turedi S, Mentese A, et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med. 2008;26:874-8.
  10. Talwalkar SS, Bon-Homme M, Miller JJ, et al. Ischemia modified albumin, a marker of acute ischemic events: A pilot study. Ann Clin Lab Sci. 2008;38:132-7.
  11. Anwaruddin S, Januzzi Jr JL, Baggish AL, et al. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol. 2005;123:140-5.
  12. Senes M, Kazan N, Coskun O, et al. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem. 2007;44:43-7.
  13. Turedi S, Gunduz A, Mentese A, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res. 2008;9:49. Gunduz A, Turkmen S, Turedi S, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med. 2009;16:539-43.
  14. Michalak S, Osztynowicz K, Płóciniczak A, et al. Ischemia-modified albümin in patients during interictal period. Journal of Medical Science. 2016;85:231-7.
  15. Spector JT, Kahn SR, Jones MR, et al. Migraine he